<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067521</url>
  </required_header>
  <id_info>
    <org_study_id>MS-GA-301</org_study_id>
    <secondary_id>2009-018084-27</secondary_id>
    <nct_id>NCT01067521</nct_id>
  </id_info>
  <brief_title>A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo</brief_title>
  <acronym>GALA</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg
      administered three times a week compared to placebo in subjects with RRMS, as measured by the
      number of confirmed relapses during the 12 month placebo controlled period. The study has two
      periods:

        -  Placebo Controlled Period: 12 months of 40 mg administered three times a week by
           subcutaneous injection or matching placebo.

        -  Open Label Extension Period: All subjects will continue treatment with GA 40 mg
           administered three times a week, until this dose strength is commercially available for
           the treatment of relapsing remitting multiple sclerosis (RRMS) patients or until the
           development of this GA dose regimen is stopped by the Sponsor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who were randomized to the GA 40 mg treatment arm in the Double-Blind Period,
      continue that treatment in the Open-Label Extension Period and are referred to as &quot;Early
      Start&quot; participants. Participants randomized to the Placebo arm in the Double-Blind Period
      and switched to GA 40 mg subcutaneous injections three times a week in the Open-Label
      Extension are referred to as &quot;Delayed Start&quot; participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2010</start_date>
  <completion_date type="Actual">May 12, 2017</completion_date>
  <primary_completion_date type="Actual">May 8, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</measure>
    <time_frame>Day 1 to 12 months</time_frame>
    <description>Relapses were monitored throughout the study. During the PC Period, two neurologists/physicians assessed subjects' general medical and neurological evaluations separately. A relapse was defined as the appearance of 1+ new neurological abnormalities or the reappearance of 1+ previously observed neurological abnormalities lasting &gt;= 48 hours and immediately preceded by an improving neurological state of at &gt;=30 days from onset of previous relapse. An event was counted as a relapse only when the subject's symptoms were accompanied by observed objective neurological changes, consistent with &gt;= one of the following: - An increase of &gt;= 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation. - An increase of one grade in the actual score of &gt;=2 of the 7 functional systems (FS), as compared to previous evaluation. - An increase of 2 grades in the actual score of one FS as compared to the previous evaluation. Adjusted mean values are displayed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression</measure>
    <time_frame>Day 1 up to 6.5 years</time_frame>
    <description>The annualized relapse rate (ARR) was calculated for the study by dividing the cumulative number of confirmed relapses by the number of person-years of exposure to treatment. The analysis of the annualized relapse rate is based on estimating a contrast (early start vs delayed start) derived from a baseline-adjusted, Negative Binomial Regression model to the number of confirmed relapses observed during study (post randomization) with an &quot;offset&quot; based on the log of exposure to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Cumulative Number of New/Enlarging T2 Lesions Taken at Month 6 and Month 12 During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</measure>
    <time_frame>Baseline (Day -7), Month 6, Month 12</time_frame>
    <description>T2 lesions are hyperintense brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. The cumulative number of T2 lesions at Months 6 and 12 that are new or enlarged as compared to the baseline MRI are offered. Note that the two timeframes (Months 6 and 12) are combined. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions and country or geographical region as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Month 6 and Month 12 of the Placebo-Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</measure>
    <time_frame>Baseline (Day -7), Month 6, Month 12</time_frame>
    <description>The cumulative number of gadolinium (Gd)-enhanced lesions on T1-weighted images at Months 6 and 12 as compared to the baseline MRI are offered. Note that the two timeframes (Months 6 and 12) are combined. Adjusted mean is based on negative binomial regression with an &quot;offset&quot; employing the log of the proportion of the number of the available post-baseline scans to adjust for missing MRI scans (if any), adjusted for baseline number of enhancing lesions on T1-weighted images and country or geographical region as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Atrophy As Defined by the Percent of Change in Normalized Brain Volume From Baseline to Month 12 During the Placebo Controlled (PC) Treatment Period</measure>
    <time_frame>Baseline (Day -7), Month 12</time_frame>
    <description>The analysis of brain atrophy as defined by the percentage change in normalized brain volume from baseline to Month 12 was based on the outcome of a contrast (GA 40 mg TIW vs. placebo) derived from a baseline-adjusted ANCOVA. In addition to the treatment group, the model included the following covariates: - SIENAX normalized brain volume at baseline. - The number of enhancing lesions on T1-weighted images at baseline. - country or geographical region.
Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression</measure>
    <time_frame>Baseline (Day -7), Month 6, Month 12, Month 36</time_frame>
    <description>All data accumulated from screening, the PC Treatment period up to the end of the Open Label (OL) period are combined and referred to as the Long Term Period. T2 lesions are hyperintense brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. The number of T2 lesions at Months 6, 12 and 36 that are new or enlarged as compared to the baseline MRI are offered. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions and country or geographical region as covariates. An &quot;offset&quot; employing the log of the proportion of the number of the available post-placebo-controlled baseline (PCBL) scans was used to adjust for missing MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression</measure>
    <time_frame>Baseline (Day -7), Month 6, Month 12, Month 36</time_frame>
    <description>All data accumulated from screening, the PC Treatment period up to the end of the Open Label (OL) period are combined and referred to as the Long Term Period. The cumulative number of gadolinium (Gd)-enhanced lesions on T1-weighted images at Months 6, 12 and 36 as compared to the baseline MRI are offered. Adjusted mean is based on negative binomial regression The model was fit using an autoregressive covariance structure. Covariates used: number of enhancing lesions on T1-weighted images at placebo-controlled baseline and country or geographical region. The cumulative number is derived from all the data points before it. For example, if the participant skipped one time point in between the baseline and 36 months, then it cannot be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Atrophy As Defined by the Percent of Change in Brain Volume From Baseline to Months 6, 12 and 36 Estimated by a Mixed Model for Repeated Measures</measure>
    <time_frame>Baseline (Day -7), Month 6, Month 12, Month 36</time_frame>
    <description>The analysis of brain atrophy as defined by the percentage change in brain volume from baseline to Months 6, 12 and 36 was performed using mixed model for repeated measures (MMRM) with SIENAX normalized brain volume at baseline, number of Gd-enhancing lesions at baseline, and country or geographical region as fixed effects.
Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Early Start: Day 1 up to 6.5 years Delayed Start - Placebo: Day 1 up to Month 12 Delayed Start - GA: Month 13 up to 6.5 years</time_frame>
    <description>Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1404</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>GA 40 mg / GA 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Also referred to as the 'Early Start' treatment arm, participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the Double-Blind Period, and then continued that treatment as open-label therapy until the drug was commercially available or development stopped.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / GA 40 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Also referred to as the 'Delayed Start' treatment arm, participants were administered placebo subcutaneous injections three times a week for 12 months during the Double-Blind Period, and then switched to GA 40 mg/mL subcutaneous injections three times a week as open-label therapy until the drug was commercially available or development stopped.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer acetate (GA)</intervention_name>
    <description>GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.</description>
    <arm_group_label>GA 40 mg / GA 40 mg</arm_group_label>
    <arm_group_label>Placebo / GA 40 mg</arm_group_label>
    <other_name>Copaxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.</description>
    <arm_group_label>Placebo / GA 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised
             McDonald criteria with a relapsing-remitting disease course.

          2. Subjects must be ambulatory with an EDSS score of 0-5.5 in both screening and baseline
             visits.

          3. Subjects must be in a relapse-free, stable neurological condition and free of
             corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or per os (PO)] or
             ACTH 30 days prior to screening (month -1) and between screening and baseline (month
             0) visits.

          4. Subjects must have experienced one of the following:

             At least one documented relapse in the 12 months prior to screening, or At least two
             documented relapses in the 24 months prior to screening, or One documented relapse
             between 12 and 24 months prior to screening with at least one documented T1-Gd
             enhancing lesion in an MRI performed within 12 months prior to screening.

          5. Subjects must be between 18 and 55 years of age, inclusive.

          6. Women of child-bearing potential must practice an acceptable method of birth control.

          7. Subjects must be able to sign and date a written informed consent prior to entering
             the study.

          8. Subjects must be willing and able to comply with the protocol requirements for the
             duration of the study

        Exclusion Criteria:

          1. Subjects with progressive forms of MS.

          2. Use of experimental or investigational drugs, and/or participation in drug clinical
             studies within the 6 months prior to screening.

          3. Use of immunosuppressive (including Mitoxantrone and Fingolimod) or cytotoxic agents
             within 6 months prior to the screening visit.

          4. Use of natalizumab (Tysabri®) or any other monoclonal antibodies within 2 years prior
             to screening.

          5. Use of cladribine within 2 years prior to screening.

          6. Previous treatment with immunomodulators (including IFNβ 1a and 1b, and IV
             Immunoglobulin (IVIg) within 2 months prior to screening.

          7. Previous use of GA or any other glatiramoid.

          8. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid
             treatment within 6 months prior to screening visit.

          9. Previous total body irradiation or total lymphoid irradiation.

         10. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone
             marrow transplantation.

         11. Pregnancy or breastfeeding.

         12. Subjects with a clinically significant or unstable medical or surgical condition that
             would preclude safe and complete study participation, as determined by medical
             history, physical exams, ECG, abnormal laboratory tests and chest X-ray. Such
             conditions may include hepatic, renal or metabolic diseases, systemic disease, acute
             infection, current malignancy or recent history (5 years) of malignancy, major
             psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be
             detrimental according to the investigator's judgment.

         13. A known history of sensitivity to Gadolinium.

         14. Inability to successfully undergo MRI scanning.

         15. A known drug hypersensitivity to Mannitol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teva Investigational Site 1332</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1327</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1311</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1326</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1335</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1297</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1344</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1315</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1350</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1345</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1336</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1347</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1319</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1298</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1316</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1340</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1317</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1303</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1334</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1302</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1322</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1306</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1329</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1349</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1313</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1318</name>
      <address>
        <city>Uniontown</city>
        <state>Ohio</state>
        <zip>44685</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1341</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1310</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1321</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1337</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1301</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1346</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1343</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1338</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1339</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1300</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1323</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5940</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5931</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5932</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5933</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5936</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5935</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5939</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5921</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5922</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5926</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5938</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5924</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5927</name>
      <address>
        <city>Sofia</city>
        <zip>15257</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5923</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5925</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5928</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5929</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5934</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5930</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5937</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6011</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6009</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6010</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6012</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6013</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5433</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5434</name>
      <address>
        <city>Ostrava - poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5432</name>
      <address>
        <city>Praha 10</city>
        <zip>100 31</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5435</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5513</name>
      <address>
        <city>Kohtla-Jarve</city>
        <zip>31025</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5510</name>
      <address>
        <city>Tallinn</city>
        <zip>EE-10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5512</name>
      <address>
        <city>Tartu</city>
        <zip>EE-51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8110</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8111</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3268</name>
      <address>
        <city>Bad Wildbad</city>
        <zip>75323</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3272</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3262</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3276</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3271</name>
      <address>
        <city>Bonn</city>
        <zip>53117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3265</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3267</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3263</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3269</name>
      <address>
        <city>Hamburg</city>
        <zip>22179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3266</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3270</name>
      <address>
        <city>Herborn</city>
        <zip>35745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3273</name>
      <address>
        <city>Kaltenkirchen</city>
        <zip>24568</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3275</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3261</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3264</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5127</name>
      <address>
        <city>Budapest</city>
        <zip>H-1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5129</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5130</name>
      <address>
        <city>Eger</city>
        <zip>H-3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5132</name>
      <address>
        <city>Esztergom</city>
        <zip>H-2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5131</name>
      <address>
        <city>Gyor</city>
        <zip>H-9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5128</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5133</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8052</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262160</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3089</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3084</name>
      <address>
        <city>Cefalu</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3092</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3080</name>
      <address>
        <city>Milano</city>
        <zip>20148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3086</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5710</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5712</name>
      <address>
        <city>Siauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5711</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5374</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5377</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5381</name>
      <address>
        <city>Gdansk</city>
        <zip>80-299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5380</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5376</name>
      <address>
        <city>Gorzow Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5372</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5375</name>
      <address>
        <city>Katowice</city>
        <zip>40-684</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5368</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5379</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5382</name>
      <address>
        <city>Konskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5369</name>
      <address>
        <city>Koscierzyna</city>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5378</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5366</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5373</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-560</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5384</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5371</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5367</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5370</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5233</name>
      <address>
        <city>Balotesti</city>
        <zip>077015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5222</name>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5221</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5220</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5227</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5230</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400437</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5225</name>
      <address>
        <city>Constanta</city>
        <zip>900123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5226</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5232</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5231</name>
      <address>
        <city>Iasi</city>
        <zip>700661</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5223</name>
      <address>
        <city>Piatra-Neamt</city>
        <zip>610136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5228</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5229</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5224</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5063</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5059</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5068</name>
      <address>
        <city>Irkutsk</city>
        <zip>664079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5067</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5052</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5057</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5062</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5060</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5053</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5058</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5064</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5056</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5055</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5054</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5066</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5061</name>
      <address>
        <city>Ufa</city>
        <zip>450007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5065</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9020</name>
      <address>
        <city>Johannesburg</city>
        <zip>2157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9019</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9022</name>
      <address>
        <city>Pietermaritzburg</city>
        <zip>3201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9025</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9018</name>
      <address>
        <city>Pretoria</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9021</name>
      <address>
        <city>Rosebank</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9024</name>
      <address>
        <city>Umhlanga</city>
        <zip>4320</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5835</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5834</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5827</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5828</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5829</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5830</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5833</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5836</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5825</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5839</name>
      <address>
        <city>Odesa</city>
        <zip>65014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5832</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5838</name>
      <address>
        <city>Simferopol</city>
        <zip>295017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5837</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5826</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5831</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3439</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3438</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3440</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <results_first_submitted>July 17, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>October 21, 2018</last_update_submitted>
  <last_update_submitted_qc>October 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>Glatiramer Acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1524 subjects were screened in this study, and 120 (7.9%) subjects failed screening. Of these, 69 did not meet inclusion or exclusion criteria, 30 withdrew from the study and 21 failed screening for other reasons.</recruitment_details>
      <pre_assignment_details>1404 subjects were enrolled and randomized in the placebo-controlled (PC) double-blind period. Participants were randomized 2:1 to the treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Early Start: GA 40 mg / GA 40 mg</title>
          <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
        </group>
        <group group_id="P2">
          <title>Delayed Start: Placebo / GA 40 mg</title>
          <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Placebo-Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="943"/>
                <participants group_id="P2" count="461"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="859"/>
                <participants group_id="P2" count="430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused to sign informed consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="834">Some participants did not continue into the open-label period.</participants>
                <participants group_id="P2" count="419">Some participants did not continue into the open-label period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Teva requested subject to be withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat (ITT) Analysis Set of Participants at the Placebo-Controlled Period Baseline</population>
      <group_list>
        <group group_id="B1">
          <title>Early Start: GA 40 mg / GA 40 mg</title>
          <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
        </group>
        <group group_id="B2">
          <title>Delayed Start: Placebo / GA 40 mg</title>
          <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="943"/>
            <count group_id="B2" value="461"/>
            <count group_id="B3" value="1404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.36" spread="9.401"/>
                    <measurement group_id="B2" value="38.12" spread="9.222"/>
                    <measurement group_id="B3" value="37.61" spread="9.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="641"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="954"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other, not specified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="916"/>
                    <measurement group_id="B2" value="455"/>
                    <measurement group_id="B3" value="1371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="934"/>
                    <measurement group_id="B2" value="460"/>
                    <measurement group_id="B3" value="1394"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>One participant in the Placebo arm was missing the BMI baseline measure.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="942"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.38" spread="4.709"/>
                    <measurement group_id="B2" value="24.44" spread="4.804"/>
                    <measurement group_id="B3" value="24.40" spread="4.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from First Symptom</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.68" spread="6.748"/>
                    <measurement group_id="B2" value="7.61" spread="6.360"/>
                    <measurement group_id="B3" value="7.66" spread="6.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Multiple Sclerosis (MS) Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.70" spread="4.982"/>
                    <measurement group_id="B2" value="3.88" spread="4.744"/>
                    <measurement group_id="B3" value="3.76" spread="4.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of T1 Gadolinium (Gd)-Enhanced Lesions per Participant at Baseline</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="4.70"/>
                    <measurement group_id="B2" value="1.4" spread="3.69"/>
                    <measurement group_id="B3" value="1.6" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of T2 Lesions Per Participant at Baseline</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="943"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="26.34"/>
                    <measurement group_id="B2" value="36.7" spread="26.68"/>
                    <measurement group_id="B3" value="37.5" spread="26.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sienax Normalized Brain Volume at Baseline</title>
          <description>Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
          <population>One participant in the GA40 mg (&quot;Early Start') arm was missing the Sienax normalized brain volume baseline measure.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="942"/>
                    <count group_id="B2" value="461"/>
                    <count group_id="B3" value="1403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1533.888" spread="110.6107"/>
                    <measurement group_id="B2" value="1537.899" spread="110.7549"/>
                    <measurement group_id="B3" value="1535.206" spread="110.6347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</title>
        <description>Relapses were monitored throughout the study. During the PC Period, two neurologists/physicians assessed subjects' general medical and neurological evaluations separately. A relapse was defined as the appearance of 1+ new neurological abnormalities or the reappearance of 1+ previously observed neurological abnormalities lasting &gt;= 48 hours and immediately preceded by an improving neurological state of at &gt;=30 days from onset of previous relapse. An event was counted as a relapse only when the subject's symptoms were accompanied by observed objective neurological changes, consistent with &gt;= one of the following: - An increase of &gt;= 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation. - An increase of one grade in the actual score of &gt;=2 of the 7 functional systems (FS), as compared to previous evaluation. - An increase of 2 grades in the actual score of one FS as compared to the previous evaluation. Adjusted mean values are displayed.</description>
        <time_frame>Day 1 to 12 months</time_frame>
        <population>Intent To Treat (ITT) Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</title>
          <description>Relapses were monitored throughout the study. During the PC Period, two neurologists/physicians assessed subjects' general medical and neurological evaluations separately. A relapse was defined as the appearance of 1+ new neurological abnormalities or the reappearance of 1+ previously observed neurological abnormalities lasting &gt;= 48 hours and immediately preceded by an improving neurological state of at &gt;=30 days from onset of previous relapse. An event was counted as a relapse only when the subject's symptoms were accompanied by observed objective neurological changes, consistent with &gt;= one of the following: - An increase of &gt;= 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation. - An increase of one grade in the actual score of &gt;=2 of the 7 functional systems (FS), as compared to previous evaluation. - An increase of 2 grades in the actual score of one FS as compared to the previous evaluation. Adjusted mean values are displayed.</description>
          <population>Intent To Treat (ITT) Analysis Population</population>
          <units>confirmed relapses</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="943"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.331" spread="0.028"/>
                    <measurement group_id="O2" value="0.505" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Relapses were estimated by a baseline-adjusted, Negative Binomial Regression with an “offset” based on the log of subject’s exposure to treatment. The model included the following covariates: - Baseline EDSS score. - Log of the prior 2-year number of relapses. - Volume of T2 lesions at baseliner. - Status of Gd-enhancing T1 activity at baseline (=0 no Gd-enhancing T1 at baseline; =1 at least one Gd-enhancing T1 at baseline). - CGR.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The overall significance level for this study is 5%</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.656</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>0.799</ci_upper_limit>
            <estimate_desc>GA 40 mg vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cumulative Number of New/Enlarging T2 Lesions Taken at Month 6 and Month 12 During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</title>
        <description>T2 lesions are hyperintense brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. The cumulative number of T2 lesions at Months 6 and 12 that are new or enlarged as compared to the baseline MRI are offered. Note that the two timeframes (Months 6 and 12) are combined. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions and country or geographical region as covariates.</description>
        <time_frame>Baseline (Day -7), Month 6, Month 12</time_frame>
        <population>ITT. When a subject had both Month 6 and Month 12 scans missing, the subject was excluded from the analysis. When the Month 12 scan was missing, data from Month 6 was used and an offset of log (0.5) introduced. When the Month 6 scan was missing, data from Month 12 was used with an offset of 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cumulative Number of New/Enlarging T2 Lesions Taken at Month 6 and Month 12 During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</title>
          <description>T2 lesions are hyperintense brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. The cumulative number of T2 lesions at Months 6 and 12 that are new or enlarged as compared to the baseline MRI are offered. Note that the two timeframes (Months 6 and 12) are combined. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions and country or geographical region as covariates.</description>
          <population>ITT. When a subject had both Month 6 and Month 12 scans missing, the subject was excluded from the analysis. When the Month 12 scan was missing, data from Month 6 was used and an offset of log (0.5) introduced. When the Month 6 scan was missing, data from Month 12 was used with an offset of 0.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="884"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.650" spread="0.259"/>
                    <measurement group_id="O2" value="5.592" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Negative binomial regression</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The overall significance level for this study is 5%</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.653</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.546</ci_lower_limit>
            <ci_upper_limit>0.780</ci_upper_limit>
            <estimate_desc>GA 40 mg vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Month 6 and Month 12 of the Placebo-Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</title>
        <description>The cumulative number of gadolinium (Gd)-enhanced lesions on T1-weighted images at Months 6 and 12 as compared to the baseline MRI are offered. Note that the two timeframes (Months 6 and 12) are combined. Adjusted mean is based on negative binomial regression with an &quot;offset&quot; employing the log of the proportion of the number of the available post-baseline scans to adjust for missing MRI scans (if any), adjusted for baseline number of enhancing lesions on T1-weighted images and country or geographical region as covariates.</description>
        <time_frame>Baseline (Day -7), Month 6, Month 12</time_frame>
        <population>ITT. When a subject had both Month 6 and Month 12 scans missing, the subject was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Month 6 and Month 12 of the Placebo-Controlled (PC) Treatment Period Estimated by Negative Binomial Regression</title>
          <description>The cumulative number of gadolinium (Gd)-enhanced lesions on T1-weighted images at Months 6 and 12 as compared to the baseline MRI are offered. Note that the two timeframes (Months 6 and 12) are combined. Adjusted mean is based on negative binomial regression with an &quot;offset&quot; employing the log of the proportion of the number of the available post-baseline scans to adjust for missing MRI scans (if any), adjusted for baseline number of enhancing lesions on T1-weighted images and country or geographical region as covariates.</description>
          <population>ITT. When a subject had both Month 6 and Month 12 scans missing, the subject was excluded from the analysis.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="884"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" spread="0.087"/>
                    <measurement group_id="O2" value="1.639" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The overall significance level for this study is 5%</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.552</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.436</ci_lower_limit>
            <ci_upper_limit>0.699</ci_upper_limit>
            <estimate_desc>GA 40 mg vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Atrophy As Defined by the Percent of Change in Normalized Brain Volume From Baseline to Month 12 During the Placebo Controlled (PC) Treatment Period</title>
        <description>The analysis of brain atrophy as defined by the percentage change in normalized brain volume from baseline to Month 12 was based on the outcome of a contrast (GA 40 mg TIW vs. placebo) derived from a baseline-adjusted ANCOVA. In addition to the treatment group, the model included the following covariates: - SIENAX normalized brain volume at baseline. - The number of enhancing lesions on T1-weighted images at baseline. - country or geographical region.
Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
        <time_frame>Baseline (Day -7), Month 12</time_frame>
        <population>ITT population of participants who had SIENEX brain volume estimates at both baseline and Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Atrophy As Defined by the Percent of Change in Normalized Brain Volume From Baseline to Month 12 During the Placebo Controlled (PC) Treatment Period</title>
          <description>The analysis of brain atrophy as defined by the percentage change in normalized brain volume from baseline to Month 12 was based on the outcome of a contrast (GA 40 mg TIW vs. placebo) derived from a baseline-adjusted ANCOVA. In addition to the treatment group, the model included the following covariates: - SIENAX normalized brain volume at baseline. - The number of enhancing lesions on T1-weighted images at baseline. - country or geographical region.
Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
          <population>ITT population of participants who had SIENEX brain volume estimates at both baseline and Month 12.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="840"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.706" spread="0.037"/>
                    <measurement group_id="O2" value="-0.645" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2058</p_value>
            <p_value_desc>The overall significance level for this study is 5%</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.154</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
            <estimate_desc>GA 40 mg vs Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression</title>
        <description>The annualized relapse rate (ARR) was calculated for the study by dividing the cumulative number of confirmed relapses by the number of person-years of exposure to treatment. The analysis of the annualized relapse rate is based on estimating a contrast (early start vs delayed start) derived from a baseline-adjusted, Negative Binomial Regression model to the number of confirmed relapses observed during study (post randomization) with an &quot;offset&quot; based on the log of exposure to treatment.</description>
        <time_frame>Day 1 up to 6.5 years</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>RParticipants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression</title>
          <description>The annualized relapse rate (ARR) was calculated for the study by dividing the cumulative number of confirmed relapses by the number of person-years of exposure to treatment. The analysis of the annualized relapse rate is based on estimating a contrast (early start vs delayed start) derived from a baseline-adjusted, Negative Binomial Regression model to the number of confirmed relapses observed during study (post randomization) with an &quot;offset&quot; based on the log of exposure to treatment.</description>
          <population>ITT</population>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="943"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2621" spread="0.0189"/>
                    <measurement group_id="O2" value="0.3146" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Entire Study The Negative Binomial Regression model covariates: • treatment group • PCBL (Placebo-Controlled Baseline) Kurtzke’s Expanded Disability Status Scale (EDSS) score as 1 degree of freedom variable • Log of the # of relapses in the 2 years prior to PCBL • Volume of T2 lesions at PCBL • Status of Gd-enhancing T1 lesion activity at PCBL (=0 if no Gd-enhancing T1 lesions at PCBL; =1 if at least one Gd-enhancing T1 lesion at PCBL) • Country or Geographical Region (CGR)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0409</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.8332</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0744</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6995</ci_lower_limit>
            <ci_upper_limit>0.9925</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression</title>
        <description>All data accumulated from screening, the PC Treatment period up to the end of the Open Label (OL) period are combined and referred to as the Long Term Period. T2 lesions are hyperintense brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. The number of T2 lesions at Months 6, 12 and 36 that are new or enlarged as compared to the baseline MRI are offered. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions and country or geographical region as covariates. An &quot;offset&quot; employing the log of the proportion of the number of the available post-placebo-controlled baseline (PCBL) scans was used to adjust for missing MRI scans.</description>
        <time_frame>Baseline (Day -7), Month 6, Month 12, Month 36</time_frame>
        <population>ITT population of participants with MRIs at both baseline and the designated timeframes.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression</title>
          <description>All data accumulated from screening, the PC Treatment period up to the end of the Open Label (OL) period are combined and referred to as the Long Term Period. T2 lesions are hyperintense brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. The number of T2 lesions at Months 6, 12 and 36 that are new or enlarged as compared to the baseline MRI are offered. Adjusted mean is based on negative binomial regression, adjusted for baseline number of T2 lesions and country or geographical region as covariates. An &quot;offset&quot; employing the log of the proportion of the number of the available post-placebo-controlled baseline (PCBL) scans was used to adjust for missing MRI scans.</description>
          <population>ITT population of participants with MRIs at both baseline and the designated timeframes.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="883"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="883"/>
                    <count group_id="O2" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.872" spread="0.214"/>
                    <measurement group_id="O2" value="3.902" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="854"/>
                    <count group_id="O2" value="425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.484" spread="0.318"/>
                    <measurement group_id="O2" value="7.086" spread="0.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="571"/>
                    <count group_id="O2" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.836" spread="0.41"/>
                    <measurement group_id="O2" value="8.759" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6 Negative binomial regression</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0056</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.736</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.592</ci_lower_limit>
            <ci_upper_limit>0.914</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12 Negative binomial regression</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.633</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>0.765</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36 Negative binomial regression</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.666</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.557</ci_lower_limit>
            <ci_upper_limit>0.797</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression</title>
        <description>All data accumulated from screening, the PC Treatment period up to the end of the Open Label (OL) period are combined and referred to as the Long Term Period. The cumulative number of gadolinium (Gd)-enhanced lesions on T1-weighted images at Months 6, 12 and 36 as compared to the baseline MRI are offered. Adjusted mean is based on negative binomial regression The model was fit using an autoregressive covariance structure. Covariates used: number of enhancing lesions on T1-weighted images at placebo-controlled baseline and country or geographical region. The cumulative number is derived from all the data points before it. For example, if the participant skipped one time point in between the baseline and 36 months, then it cannot be calculated.</description>
        <time_frame>Baseline (Day -7), Month 6, Month 12, Month 36</time_frame>
        <population>ITT population of participants with MRIs at both baseline and the designated timeframes, inclusive of the proceeding post-baseline timeframes.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression</title>
          <description>All data accumulated from screening, the PC Treatment period up to the end of the Open Label (OL) period are combined and referred to as the Long Term Period. The cumulative number of gadolinium (Gd)-enhanced lesions on T1-weighted images at Months 6, 12 and 36 as compared to the baseline MRI are offered. Adjusted mean is based on negative binomial regression The model was fit using an autoregressive covariance structure. Covariates used: number of enhancing lesions on T1-weighted images at placebo-controlled baseline and country or geographical region. The cumulative number is derived from all the data points before it. For example, if the participant skipped one time point in between the baseline and 36 months, then it cannot be calculated.</description>
          <population>ITT population of participants with MRIs at both baseline and the designated timeframes, inclusive of the proceeding post-baseline timeframes.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="883"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="883"/>
                    <count group_id="O2" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.629" spread="0.072"/>
                    <measurement group_id="O2" value="1.131" spread="9.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="854"/>
                    <count group_id="O2" value="425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.054" spread="0.115"/>
                    <measurement group_id="O2" value="2.051" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="570"/>
                    <count group_id="O2" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.501" spread="0.168"/>
                    <measurement group_id="O2" value="2.265" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.556</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.093</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>0.773</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.514</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.073</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.388</ci_lower_limit>
            <ci_upper_limit>0.679</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.663</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.514</ci_lower_limit>
            <ci_upper_limit>0.854</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Atrophy As Defined by the Percent of Change in Brain Volume From Baseline to Months 6, 12 and 36 Estimated by a Mixed Model for Repeated Measures</title>
        <description>The analysis of brain atrophy as defined by the percentage change in brain volume from baseline to Months 6, 12 and 36 was performed using mixed model for repeated measures (MMRM) with SIENAX normalized brain volume at baseline, number of Gd-enhancing lesions at baseline, and country or geographical region as fixed effects.
Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
        <time_frame>Baseline (Day -7), Month 6, Month 12, Month 36</time_frame>
        <population>ITT population of participants with SIENEX brain scans at both baseline and the designated timeframes.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: Placebo / GA 40 mg</title>
            <description>Participants were administered placebo subcutaneous injections three times a week for 12 months during the double-blind Placebo-Controlled Period. Participants were then switched to glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week during the Open-Label Period from Month 13 up to Year 6.5 until the study ended.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Atrophy As Defined by the Percent of Change in Brain Volume From Baseline to Months 6, 12 and 36 Estimated by a Mixed Model for Repeated Measures</title>
          <description>The analysis of brain atrophy as defined by the percentage change in brain volume from baseline to Months 6, 12 and 36 was performed using mixed model for repeated measures (MMRM) with SIENAX normalized brain volume at baseline, number of Gd-enhancing lesions at baseline, and country or geographical region as fixed effects.
Sienax estimates total brain tissue volume, from a single image, normalised for skull size.</description>
          <population>ITT population of participants with SIENEX brain scans at both baseline and the designated timeframes.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="436"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="872"/>
                    <count group_id="O2" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.429" spread="0.032"/>
                    <measurement group_id="O2" value="-0.345" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="846"/>
                    <count group_id="O2" value="423"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.739" spread="0.035"/>
                    <measurement group_id="O2" value="-0.653" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="543"/>
                    <count group_id="O2" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.935" spread="0.063"/>
                    <measurement group_id="O2" value="-1.952" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0425</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Mixed model for repeated measures (MMRM)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.166</ci_lower_limit>
            <ci_upper_limit>-0.003</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0844</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Mixed model for repeated measures (MMRM)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.184</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8701</p_value>
            <p_value_desc>not adjusted for multiplicity</p_value_desc>
            <method>Mixed model for repeated measures (MMRM)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.106</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
            <estimate_desc>Early Start vs Delayed Start</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.</description>
        <time_frame>Early Start: Day 1 up to 6.5 years Delayed Start - Placebo: Day 1 up to Month 12 Delayed Start - GA: Month 13 up to 6.5 years</time_frame>
        <population>Glatiramer Acetate (GA) - Treated Analysis Set The GA-Treated analysis set includes all subjects randomized into the study and treated with at least 1 dose of GA at any time during the study. Analyses includes data collected for these subjects from the first time GA was administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Start: GA 40 mg / GA 40 mg</title>
            <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended</description>
          </group>
          <group group_id="O2">
            <title>Delayed Start: GA 40 mg</title>
            <description>After completing the double-blind Placebo-Controlled Period, participants had the option of continuing in the study on glatiramer acetate (GA) 40 mg/ml by subcutaneous injection three times a week until the study ended. This 'Delayed Start' treatment began at Month 13 and continued until the study ended (up to about 6.5 years).</description>
          </group>
          <group group_id="O3">
            <title>Delayed Start: Placebo</title>
            <description>Participants were administered placebo subcutaneous injections three times a week from Day 1 to Month 12 during the double-blind Placebo-Controlled Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.</description>
          <population>Glatiramer Acetate (GA) - Treated Analysis Set The GA-Treated analysis set includes all subjects randomized into the study and treated with at least 1 dose of GA at any time during the study. Analyses includes data collected for these subjects from the first time GA was administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="943"/>
                <count group_id="O2" value="419"/>
                <count group_id="O3" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="777"/>
                    <measurement group_id="O2" value="322"/>
                    <measurement group_id="O3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of TEAEs: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="698"/>
                    <measurement group_id="O2" value="283"/>
                    <measurement group_id="O3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of TEAEs: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of TEAEs: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Delayed Start (GA 40 mg): Month 13 up to 6.5 years Delayed Start (Placebo): Day 1 to Month 12 Early Start: (GA 40 mg/ GA 40 mg) Day 1 up to 6.5 years</time_frame>
      <desc>Death details:
Delayed Start (GA 40 mg): caused by subarachnoid hemorrhage and brain edema 1027 days after the first dose of GA.
Delayed Start (Placebo): cardiopulmonary failure
Early Start: Three deaths due to acute cardiac failure, cardio-respiratory arrest, and cardiac arrest occurring 488, 1283 and 1682 days after first dose of GA respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Delayed Start: GA 40 mg</title>
          <description>After completing the double-blind Placebo-Controlled Period, participants had the option of continuing in the study on glatiramer acetate (GA) 40 mg/ml by subcutaneous injection three times a week until the study ended. This 'Delayed Start' treatment started at Month 13 and continued until the study ended (up to about 6.5 years).</description>
        </group>
        <group group_id="E2">
          <title>Delayed Start: Placebo</title>
          <description>Participants were administered placebo subcutaneous injections three times a week from Day 1 to Month 12 during the double-blind Placebo-Controlled Period.</description>
        </group>
        <group group_id="E3">
          <title>Early Start: GA 40 mg / GA 40 mg</title>
          <description>Participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the double-blind Placebo-Controlled Period, and then continued that treatment in the Open-label Period from Month 13 up to Year 6.5 until the study ended</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="461"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Immediate post-injection reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Fractured skull depressed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Astrocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Apallic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Idiopathic generalised epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Perinephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Uterine cervical erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Breast conserving surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Cervix operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Ureteric calculus removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="461"/>
                <counts group_id="E3" subjects_affected="609" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="122" subjects_affected="107" subjects_at_risk="419"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="461"/>
                <counts group_id="E3" events="391" subjects_affected="243" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="61" subjects_affected="55" subjects_at_risk="419"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="461"/>
                <counts group_id="E3" events="138" subjects_affected="115" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E3" events="95" subjects_affected="68" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="419"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="461"/>
                <counts group_id="E3" events="95" subjects_affected="50" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="419"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="461"/>
                <counts group_id="E3" events="65" subjects_affected="50" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="419"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="461"/>
                <counts group_id="E3" events="103" subjects_affected="67" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="98" subjects_affected="56" subjects_at_risk="419"/>
                <counts group_id="E2" events="47" subjects_affected="39" subjects_at_risk="461"/>
                <counts group_id="E3" events="346" subjects_affected="167" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="54" subjects_affected="32" subjects_at_risk="419"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="461"/>
                <counts group_id="E3" events="158" subjects_affected="98" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="50" subjects_affected="36" subjects_at_risk="419"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="461"/>
                <counts group_id="E3" events="165" subjects_affected="103" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="419"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="461"/>
                <counts group_id="E3" events="150" subjects_affected="98" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="83" subjects_affected="39" subjects_at_risk="419"/>
                <counts group_id="E2" events="71" subjects_affected="55" subjects_at_risk="461"/>
                <counts group_id="E3" events="316" subjects_affected="132" subjects_at_risk="943"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="419"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="461"/>
                <counts group_id="E3" events="63" subjects_affected="48" subjects_at_risk="943"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor’s review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor’s designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analyses of Open-Label Period data are not adjusted for multiplicity and therefore do not control for type one statistical error.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Branded Pharmaceutical Products, R&amp;D Inc</organization>
      <phone>001-215-591-3000</phone>
      <email>info.era-clinical@teva.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

